Document Detail

Neoadiuvant treatment with intravesical interleukin-2 for recurrent superficial transitional bladder carcinoma Ta-T1/G1-2.
MedLine Citation:
PMID:  11265776     Owner:  NLM     Status:  MEDLINE    
The aim of this study was to evaluate the direct action of IL-2 on recurrent superficial transitional bladder carcinoma and the effect on recurrence rate. 27 patients were submitted to neoadjuvant treatment by intra-vesical instillation of recombinant IL-2 and to transurethral resection. We did not observe any effect on neoplasms but the recurrence rate was less than the expected one. It is possible that treatment of bladder carcinoma with intra-vesical instillation of IL-2 may promote immuno-prophilaxis.
M Grasso; F Torelli; G Scannapieco; F Franzoso; C Lania
Related Documents :
8687346 - Acute morbidity of radiation therapy for prostate carcinoma.
7650666 - Choriocarcinoma of the bladder. report of a case of primary tumor or late metastasis of...
1877116 - Will rogers and the results of radical cystectomy for invasive bladder cancer.
10087396 - Small cell carcinoma of the urinary bladder treated with chemotherapy and radiotherapy:...
19050976 - Synchronous hepatic metastases from colon cancer: changing treatment strategies and res...
15550866 - Clinical experience of weekly paclitaxel-based treatment as preoperative chemotherapy f...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of immunotherapy (Hagerstown, Md. : 1997)     Volume:  24     ISSN:  1524-9557     ISO Abbreviation:  J. Immunother.     Publication Date:    2001 Mar-Apr
Date Detail:
Created Date:  2001-03-26     Completed Date:  2001-05-31     Revised Date:  2008-03-18    
Medline Journal Info:
Nlm Unique ID:  9706083     Medline TA:  J Immunother     Country:  United States    
Other Details:
Languages:  eng     Pagination:  184-7     Citation Subset:  IM    
Department of Urology, Desio Hospital, Milan, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Carcinoma, Transitional Cell / drug therapy*,  pathology,  surgery
Chemotherapy, Adjuvant
Interleukin-2 / administration & dosage*,  therapeutic use
Middle Aged
Neoplasm Recurrence, Local
Recombinant Proteins / administration & dosage,  therapeutic use
Urinary Bladder / drug effects
Urinary Bladder Neoplasms / drug therapy*,  pathology,  surgery
Reg. No./Substance:
0/Interleukin-2; 0/Recombinant Proteins

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Mannan mucin-1 peptide immunization: influence of cyclophosphamide and the route of injection.
Next Document:  A prospective, randomized, double-blind, placebo-controlled trial evaluating the effect of nystatin ...